Medpace Holdings, Inc. reported significant financial growth in its latest quarterly filing, with net revenue reaching $716 million for the three months ended September 30, 2026, an increase of 8.5% from $659.9 million in the same period last year. For the nine months ended September 30, 2026, revenue rose by 16.9% to $2.13 billion, compared to $1.82 billion for the corresponding period in 2025. The company's net income also saw a notable increase, rising to $137.5 million for the third quarter, up from $111.1 million a year earlier, and $382.7 million for the nine-month period, compared to $316 million in 2025.

The increase in revenue was primarily driven by growth in the Metabolic, Oncology, and Central Nervous System therapeutic areas. Total direct costs rose to $492.1 million for the third quarter, up from $463 million, largely due to higher reimbursed out-of-pocket expenses and increased personnel costs. Selling, general, and administrative expenses increased slightly to $51.8 million for the quarter, while decreasing to $147.8 million for the nine-month period, reflecting a reduction in stock-based compensation expenses.

Operationally, Medpace reported a total employee count of approximately 6,600 across 46 countries as of September 30, 2026. The company’s backlog increased by 5.6% to $3.17 billion compared to $3 billion a year prior, indicating a strong pipeline of future revenue. The company also noted that it had cash and cash equivalents of $705.3 million at the end of the reporting period, up from $497 million at the end of 2025, providing a solid liquidity position for ongoing operations and potential investments.

In terms of strategic developments, Medpace did not execute any share repurchases during the third quarter but repurchased 705,616 shares for $294.7 million during the nine months ended September 30, 2026. The company has a remaining authorization of $527 million under its share repurchase program, which was recently amended to allow for up to $1 billion in future repurchases. Looking ahead, Medpace anticipates continued growth driven by its disciplined operating model and expansion into new markets, while also focusing on potential acquisitions to enhance its service offerings.

About Medpace Holdings, Inc.

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) providing full-service Phase I-IV clinical development services to the biotech, pharmaceutical, and medical device industries. Focused on therapeutic areas like Oncology, CNS, and Cardiovascular, it supports drug development through trial management, regulatory guidance, data sciences, and laboratory services. Its business model emphasizes quality, efficiency, and deep therapeutic expertise to serve small and mid-sized biopharma companies worldwide.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov